Ozone therapy is being explored by integrative practitioners for allergic conditions including allergic rhinitis, asthma, and food sensitivities, based on its documented ability to modulate immune responses. Allergies are fundamentally an immune system problem: the body overreacts to harmless substances (pollen, dust, food proteins) by mounting a Th2-dominated inflammatory response. Ozone’s ability to shift immune signaling and reduce inflammatory cytokines makes it a theoretical candidate for allergy management. But the gap between theoretical mechanism and clinical proof is wide, and patients considering ozone for allergies need an honest assessment of what the evidence does and does not show.
Key Takeaways
- Ozone therapy modulates Th1/Th2 immune balance, which is relevant to allergic conditions where Th2 dominance drives symptoms1
- Minor autohemotherapy (mAHT) is the most commonly used ozone modality for allergies, involving injection of a small amount of ozonated blood intramuscularly2
- A few small studies suggest ozone may reduce allergic rhinitis symptoms and IgE levels, but no large randomized controlled trial has been published3
- For asthma, ozone is particularly controversial because ozone itself is a respiratory irritant at high concentrations
- Conventional allergen immunotherapy (allergy shots/drops) has decades of RCT evidence and should be considered before ozone4
- MAH sessions for allergies cost $200-400 each, with protocols typically running 10-20 sessions; insurance does not cover this use
How Allergies Work: The Immune Imbalance
Allergic diseases share a common immune mechanism. When a genetically predisposed person encounters an allergen, their immune system produces excess IgE antibodies. These IgE molecules bind to mast cells and basophils. On subsequent exposure, the allergen cross-links the IgE, triggering mast cell degranulation and release of histamine, leukotrienes, and other inflammatory mediators.4
This process is driven by T-helper 2 (Th2) cell dominance. In healthy immune function, Th1 and Th2 responses are balanced. In allergic individuals, the balance tips toward Th2, which promotes IgE production, eosinophil recruitment, and mucus secretion.
| Allergic Condition | Prevalence | Key Mediators | Standard Treatment |
|---|---|---|---|
| Allergic rhinitis | 10-30% of adults | Histamine, IgE, eosinophils | Antihistamines, nasal corticosteroids, immunotherapy |
| Allergic asthma | ~8% of population | IgE, leukotrienes, Th2 cytokines | Inhaled corticosteroids, bronchodilators, biologics |
| Food allergies | ~6-8% of children, ~2-3% of adults | IgE (immediate) or IgG/immune complex (delayed) | Avoidance, epinephrine, oral immunotherapy (OIT) |
| Atopic dermatitis | ~10-20% of children | IgE, Th2 cytokines, barrier dysfunction | Emollients, topical steroids, calcineurin inhibitors, dupilumab |
How Ozone Therapy Might Affect Allergies
The theoretical basis for ozone in allergies centers on immune modulation. At therapeutic doses, ozone produces several effects relevant to allergic inflammation:1
- Th1/Th2 rebalancing: Ozone has been shown to promote interferon-gamma (a Th1 cytokine) production while potentially dampening Th2 responses. This shift could theoretically reduce the Th2 dominance that drives allergic disease.
- NF-kB modulation: Ozone can modulate the NF-kB inflammatory pathway, which is activated in allergic inflammation and drives the production of pro-allergic cytokines (IL-4, IL-5, IL-13).
- Nrf2 activation: By upregulating antioxidant defenses, ozone may reduce the oxidative stress that worsens allergic airway inflammation.5
- Regulatory T cell induction: Some researchers propose that ozone may promote regulatory T cells (Tregs), which suppress excessive immune responses. This is the same mechanism by which successful allergen immunotherapy works.
Ozone Modalities Used for Allergies
Minor Autohemotherapy (mAHT)
Minor autohemotherapy is the most commonly used ozone modality for allergic conditions. The procedure involves:
- Drawing 2-5 mL of the patient’s blood
- Mixing it with ozone/oxygen gas (typically 10-20 mcg/mL)
- Injecting the ozonated blood intramuscularly (usually into the gluteal muscle)
This creates a localized immune response at the injection site, theoretically stimulating immune modulation without the systemic effects of MAH. Practitioners who use mAHT for allergies typically administer 1-2 sessions per week for 10-20 weeks.2
Major Autohemotherapy (MAH)
MAH involves drawing 100-200 mL of blood, ozonating it, and reinfusing it. It produces a more systemic immune effect than mAHT and is used for patients with multiple allergic conditions or severe symptoms.
Rectal Insufflation
Some practitioners use rectal ozone insufflation for food sensitivities and gut-related allergic conditions, theorizing that the gut-associated lymphoid tissue (GALT) plays a central role in food allergy immune dysregulation.
“The concept of using ozone to shift Th1/Th2 balance is immunologically plausible. But plausible mechanism is not the same as clinical proof, and patients deserve to know that difference before investing thousands of dollars in treatment.”
What Does the Evidence Show?
The evidence for ozone therapy in allergic conditions is preliminary at best:
Allergic Rhinitis
A small study by Hernandez Rosales et al. reported that minor autohemotherapy reduced nasal symptoms and serum IgE levels in patients with allergic rhinitis compared to baseline. However, the study lacked a placebo control group, and the improvement could reflect natural seasonal variation or placebo response.3
Another uncontrolled study from Cuba reported similar improvements in rhinitis symptoms after 15 sessions of mAHT, with effects lasting 6-12 months in some patients.
Asthma
The use of ozone for asthma is particularly controversial. Environmental ozone (smog) is a well-established trigger for asthma exacerbations. However, proponents argue that medical-grade ozone at controlled therapeutic doses works through different mechanisms than inhaled environmental ozone.5
Important distinctions:
- Environmental ozone: Inhaled directly into the lungs at varying concentrations, causing epithelial damage and airway inflammation
- Medical ozone (MAH/mAHT): Contacts blood ex vivo, never reaches the lungs directly. The immune effects are mediated by lipid oxidation products and cytokine changes, not by ozone itself entering the airways
Despite this distinction, no clinical trial has studied MAH or mAHT specifically for asthma. The theoretical rationale exists, but the clinical data does not.
Food Sensitivities
The evidence for ozone and food sensitivities is entirely anecdotal. Some practitioners report that patients tolerate previously problematic foods after a course of ozone therapy, but no controlled study has investigated this claim.
Cost Comparison: Ozone vs. Conventional Allergy Treatment
| Treatment | Annual Cost | Evidence Level | Insurance Coverage |
|---|---|---|---|
| Antihistamines (OTC) | $50-200 | Strong (multiple RCTs) | OTC, no Rx needed |
| Nasal corticosteroids | $100-300 | Strong (multiple RCTs) | Often covered |
| Allergy immunotherapy (SCIT) | $1,000-4,000 | Strong (100+ years of data) | Usually covered |
| Sublingual immunotherapy (SLIT) | $1,500-3,000 | Strong (multiple RCTs) | Sometimes covered |
| Biologics (omalizumab/Xolair) | $15,000-30,000 | Strong (phase 3 RCTs) | Covered for severe cases |
| Ozone therapy (mAHT) | $2,000-8,000 | Weak (uncontrolled studies) | Not covered |
| Ozone therapy (MAH) | $4,000-16,000 | Weak (uncontrolled studies) | Not covered |
Allergen Immunotherapy: The Evidence-Based Comparison
Allergen immunotherapy (AIT) is the closest conventional analog to what ozone practitioners claim. AIT also modulates the immune system to reduce allergic reactivity, but it does so through well-characterized mechanisms with over a century of clinical evidence:4
- Induces blocking IgG4 antibodies that compete with IgE
- Promotes regulatory T cells
- Shifts Th2 to Th1 response
- Provides disease modification (benefits persist after treatment stops)
- Reduces new sensitizations and prevents asthma development in allergic rhinitis patients
AIT achieves 60-90% symptom reduction in allergic rhinitis over 3-5 years of treatment. No ozone study has demonstrated anything comparable.
Safety Considerations
- Ozone is a respiratory irritant. Asthma patients considering ozone therapy must ensure the treatment involves no inhalation exposure. MAH and mAHT do not involve inhalation, but improperly administered ozone in poorly ventilated rooms could trigger bronchospasm.
- Minor autohemotherapy injection reactions: Local pain, swelling, and redness at the injection site are common. Systemic flu-like symptoms can occur.
- G6PD deficiency: An absolute contraindication for ozone therapy.1
- Drug interactions: No significant interactions are documented, but patients on immunosuppressants should consult their prescriber before adding immune-modulating therapies.
Bottom Line
Ozone therapy for allergies rests on a plausible immunological theory: shifting Th1/Th2 balance to reduce allergic overreactivity. A handful of small, uncontrolled studies suggest possible benefit for allergic rhinitis. But the evidence is far too thin to recommend ozone over established treatments. Antihistamines, nasal corticosteroids, and allergen immunotherapy all have strong evidence bases, are widely available, and in many cases are covered by insurance.
If you have exhausted conventional allergy treatments and are interested in exploring ozone, minor autohemotherapy is the most commonly used modality. Choose a practitioner who uses objective measures (IgE levels, symptom scores, pulmonary function tests) to track whether the treatment is working, and set a clear endpoint for evaluation rather than committing to an indefinite series of sessions.
References
- Viebahn-Haensler R, Leon Fernandez OS. “Ozone in medicine. The low-dose ozone concept and its basic biochemical mechanisms of action in chronic inflammatory diseases.” International Journal of Molecular Sciences, 2021;22(15):7890. DOI: 10.3390/ijms22157890
- Bocci V. Ozone: A New Medical Drug. 2nd ed. Springer; 2011. DOI: 10.1007/978-90-481-9234-2
- Hernandez Rosales FA, Calunga Fernandez JL, Turrent Figueras J, et al. “Ozone therapy effects on biomarkers and lung function in asthma.” Archives of Medical Research, 2005;36(5):549-554. DOI: 10.1016/j.arcmed.2005.04.021
- Dhami S, Kakourou A, Asamoah F, et al. “Allergen immunotherapy for allergic asthma: a systematic review and meta-analysis.” Allergy, 2017;72(12):1825-1848. DOI: 10.1111/all.13208
- Hernandez Rosales FA, Calunga JL, Turrent Figueras J, et al. “Ozone therapy effects on blood oxidative stress markers in COPD patients.” Mediators of Inflammation, 2012;2012:657340. DOI: 10.1155/2012/657340
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
